Paper · 41398592
Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib.
Huang SY and 7 others. BMC Med, 2025. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib. Papers, record 41398592. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41398592
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sunitinib | Major topic |
| Benzhydryl Compounds | Major topic |
| Carcinoma, Renal Cell | Major topic |
| Glucosides | Major topic |
| Kidney Neoplasms | Major topic |
| PPAR alpha | Major topic |
| AMP-Activated Protein Kinases | Major topic |
| Cardiotoxicity | Major topic |
| Antineoplastic Agents | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Mice, Inbred C57BL | |
| Cell Line, Tumor | |
| Apoptosis | |
| Male | |
| Xenograft Model Antitumor Assays | |
| Sodium-Glucose Transporter 2 Inhibitors |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No. 82372200 | National Natural Science Foundation of China | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37,877,337 | Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms? | Eur J Heart Fail | 2023 | https://conductscience.org/library/papers/37877337 | PubMed |
| 2 | 26,241,060 | Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis. | J Clin Invest | 2015 | https://conductscience.org/library/papers/26241060 | PubMed |
| 3 | 17,360,992 | The failing heart--an engine out of fuel. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17360992 | PubMed |
| 4 | 28,763,435 | Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma. | Med Sci Monit | 2017 | https://conductscience.org/library/papers/28763435 | PubMed |
| 5 | 32,539,724 | Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. | Cardiovasc Diabetol | 2020 | https://conductscience.org/library/papers/32539724 | PubMed |
| 6 | 25,654,551 | Autophagy in cardiovascular biology. | J Clin Invest | 2015 | https://conductscience.org/library/papers/25654551 | PubMed |
| 7 | 37,291,168 | Tisp40 prevents cardiac ischemia/reperfusion injury through the hexosamine biosynthetic pathway in male mice. | Nat Commun | 2023 | https://conductscience.org/library/papers/37291168 | PubMed |
| 8 | 31,220,942 | S100a8/a9 Signaling Causes Mitochondrial Dysfunction and Cardiomyocyte Death in Response to Ischemic/Reperfusion Injury. | Circulation | 2019 | https://conductscience.org/library/papers/31220942 | PubMed |
| 9 | 38,607,560 | Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α. | Eur Heart J | 2024 | https://conductscience.org/library/papers/38607560 | PubMed |
| 10 | 19,453,268 | Sunitinib in solid tumors. | Expert Opin Investig Drugs | 2009 | https://conductscience.org/library/papers/19453268 | PubMed |
1 to 10 of 60
See all 60 referencesCited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42,984,542 | From cancer safety signals to cardio-oncology translation: a dual-database bibliometric and BERTopic semantic analysis of SGLT2 inhibitor research in oncology (2014-2026). | Front Oncol | 2026 | https://conductscience.org/library/papers/42984542 |
Source PubMed
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41398592
GET https://conductscience.org/api/papers/v1/41398592/references?page=2